Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03160027 · ClinicalTrials.gov registry record · NA
Photobiomodulation for Improving Brain Function in Dementia (PBM Dementia)
A NA study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT03160027 is a NA study that has completed, run by University of California, San Francisco. The registered enrollment target is 20 participants.
The verdict
NCT03160027, a NA study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
A recent study (Saltmarche et al., 21017) examined the effects of photobiomodulation (PBM), a kind of light therapy that uses red or near-infrared light to heal and protect tissue that has either been injured, is degenerating, or else is at risk of dying, in 5 older adults with dementia. After 12 weeks of PBM treatments, delivered with a commercially available, wearable device, the patients with mild to moderately severe dementia showed improvements on the Mini-mental State Exam (MMSE, p\<0.003) and Alzheimer's Disease Assessment Scale-cognitive, ADAS-cog, p\<0.03). The caregivers, who kept daily journals of their experiences during the 12 weeks of PBM treatment, reported better sleep, fewer angry outbursts, decreased anxiety and wandering in their loved-ones with dementia. The goals of this trial are to: (1) replicate this finding in a larger group of individuals with dementia and (2) to examine the underling brain mechanisms behind the changes in cognitive function.
Interventions
- DEVICE Vielight Neuro Gamma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-05-15 |
| Est. Completion | 2020-09-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03160027
The ClinicalTrials.gov registry entry for NCT03160027 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vielight Neuro Gamma is the first listed.
NCT03160027 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03160027 about?
NCT03160027 is a clinical study titled "Photobiomodulation for Improving Brain Function in Dementia (PBM Dementia)". A recent study (Saltmarche et al., 21017) examined the effects of photobiomodulation (PBM), a kind of light therapy that uses red or near-infrared light to heal and protect tissue that has either been injured, is degenerating, or else is at risk of dying, in 5 older adults with dementia. After 12 we...
What is the current status of trial NCT03160027?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2017-05-15. Estimated completion is 2020-09-15.
What interventions are being tested in trial NCT03160027?
The interventions under investigation include: Vielight Neuro Gamma (DEVICE).
Who is sponsoring clinical trial NCT03160027?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.